Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.76 |
| ▸ | ESRRG | P62508 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.76 |
| ▸ | ESRRB | O95718 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | PGR | P06401 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | PLD2 | O14939 | 1/20 | 0.76 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miproxifene SCHEMBL409028 | 1.00 | ESR1 (0.76) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL409027 | 1.00 | ESR1 (0.76) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857626 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857619 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL9857612 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL2128564 | 0.99 | ESR1 (0.74) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL3781209 | 0.94 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL430163 | 0.94 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| Miproxifene SCHEMBL3781215 | 0.94 | ESR1 (0.69) | ESR1ESR2ESRRGMAPTCYP3A4 | |
| SCHEMBL9857240 | 0.91 | ESR1 (0.90) | ESR1ESR2ESRRGMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| US-20250059301-A1 | Fusion Protein Construct | NORTHWESTERN UNIVERSITY | 2025-02-20 | — | — | US | claimed |
| US-20230338355-A1 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. | 2023-10-26 | — | — | US | claimed |
| WO-2022026901-A2 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20210060052-A1 | IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE | ATOSSA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | US | claimed |
| EP-3765007-A1 | IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE | Atossa Therapeutics, Inc. (US) | 2021-01-20 | — | — | EP | claimed |
| US-20210000920-A1 | INTRADUCTAL METHODS OF TREATMENT OF BREAST DISORDERS | ATOSSA THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | US | claimed |
| EP-3727403-A1 | INTRADUCTAL METHODS OF TREATMENT OF BREAST DISORDERS | Atossa Therapeutics, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-10561648-B2 | Inhibition and treatment of bacterial infections by sex-specific GPER targeting | STC.UNM (US) | 2020-02-18 | — | — | US | claimed |
| WO-2019177991-A1 | IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE | ATOSSA GENETICS, INC. (US) | 2019-09-19 | — | — | WO | claimed |
| JP-2006519264-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| CN-1660437-A | Combination of slow released anticancer medication | LANJIN BIOLOG ENGINEERING CO L (CN) | 2005-08-31 | — | — | CN | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| EP-1465619-A1 | SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR | Nordic Bioscience A/S (DK) | 2004-10-13 | — | — | EP | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2003070253-A1 | ESTROGENIC COMPONENT FOR TREATING DECREASED LIBIDO IN WOMEN | PANTARHEI BIOSCIENCE B.V. (NL) | 2003-08-28 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003063859-A1 | SUPPRESSION OF CARTILAGE DEGRADATION VIA THE ESTROGEN RECEPTOR | NORDIC BIOSCIENCE A/S (DK) | 2003-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | STAT3, JAK2, JAK1 | ESR1 4633/4885ESR2 4402/4885ESRRG 3780/4885 |
| US-10561648-B2 | Inhibition and treatment of bacterial infections by sex-specific GPER targeting | GPER1, GPBAR1, ESR1 | ESR1 3/4885ESR2 7/4885ESRRG 4/4885 |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | VHL, HCCS, CDK4 | ESR1 4454/4885ESR2 3380/4885ESRRG 4154/4885 |
| US-20250059301-A1 | Fusion Protein Construct | RPS27A, CD2BP2, JMJD7 | ESR1 2980/4885ESR2 3683/4885ESRRG 2696/4885 |
| US-20230338355-A1 | NK ANTAGONISTS FOR CONTRACEPTION | KLKB1, KLK3, SHBG | ESR1 1083/4885ESR2 677/4885ESRRG 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.